Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Cosimo Brunetti"'
Autor:
Lucia Fratino, A Latorre, Antonio Rinaldi, Zaira Coccorullo, Palma Fedele, Salvatore Spazzapan, Vito Lorusso, Lazzaro Repetto, Ermenegildo Arnoldi, Laura Biganzoli, Mimma Raffaele, L. Petrucelli, Saverio Cinieri, Mariangela Ciccarese, Giovanna Campanella, Caterina Accettura, Luigi Coltelli, Salvatore Pisconti, Silvana Leo, Cosimo Brunetti, Marina Elena Cazzaniga
Publikováno v:
The Oncologist. 24:e232-e240
Background Metastatic breast cancer (MBC) is highly prevalent in middle-aged or elderly patients. Eribulin is a nontaxane microtubule inhibitor, approved for the treatment of pretreated MBC. This multicentric study (sponsored by GIOGer, Italian Group
Autor:
Giuseppe, Colucci, Vittorio, Gebbia, Giancarlo, Paoletti, Francesco, Giuliani, Michele, Caruso, Nicola, Gebbia, Giacomo, Cartenì, Biagio, Agostara, Giuseppe, Pezzella, Luigi, Manzione, Nicola, Borsellino, Andrea, Misino, Sante, Romito, Ernesto, Durini, Stefano, Cordio, Marisa, Di Seri, Massimo, Lopez, Evaristo, Maiello, Severino, Montemurro, Antonio, Cramarossa, Vito, Lorusso, Maurizio, Di Bisceglie, Maurizio, Chiarenza, Maria Rosaria, Valerio, Teresa, Guida, Vita, Leonardi, Salvatore, Pisconti, Gerardo, Rosati, Francesco, Carrozza, Giuseppe, Nettis, Matteo, Valdesi, Gianfranco, Filippelli, Santo, Fortunato, Sergio, Mancarella, Cosimo, Brunetti
Publikováno v:
Journal of Clinical Oncology. 23:4866-4875
Purpose We performed this phase III study to compare the irinotecan, leucovorin (LV), and fluorouracil (FU) regimen (FOLFIRI) versus the oxaliplatin, LV, and FU regimen (FOLFOX4) in previously untreated patients with advanced colorectal cancer. Patie
Autor:
Pasquale Comella, Roberta D’Aniello, Renato Giordano, Giuseppe Comella, Cosimo Brunetti, Massimiliano D’Aiuto, D Muci, Ignazio Carreca, Giuseppe DeCataldis, Sergio Palmeri, Anna Russo, Giuseppe Frasci
Publikováno v:
Oncology. 68:223-229
Purpose: The present study was aimed at defining the antitumor activity of the cisplatin-epirubicin-paclitaxel (PET) weekly administration with granulocyte colony-stimulating factor (G-CSF) support in chemonaive small-cell lung cancer patients with e
Autor:
Giuseppe Comella, Pasquale Comella, Cosimo Brunetti, Giuseppe Frasci, Ignazio Carreca, Sergio Palmeri, D. Muci, G DeCataldis, Antonio Russo, G.P. Nicolella, N. Panza, Michele Di Natale, Francovito Piantedosi
Publikováno v:
British Journal of Cancer
The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC). Chemonaive ED-SCLC patients received c
Autor:
Giuseppe, Frasci, Pasquale, Comella, Ignazio, Carreca, Giuseppe, DeCataldis, Domenico, Muci, Cosimo, Brunetti, Anna, Russo, Sergio, Palmeri, Roberta, D'Aniello, Renato, Giordano, Massimiliano, D'Aiuto, Giuseppe, Comella
Purpose: The present study was aimed at defining the antitumor activity of the cisplatin-epirubicin-paclitaxel (PET) weekly administration with granulocyte colony-stimulating factor (G-CSF) support in chemonaive small-cell lung cancer patients with e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::2a449200b3598931a2ca3be20b319632
http://hdl.handle.net/10447/12447
http://hdl.handle.net/10447/12447
Autor:
Vito, Lorusso, Domenico, Galetta, Francesco, Giotta, Antonio, Rinaldi, Sante, Romito, Cosimo, Brunetti, Nicola, Silvestris, Giuseppe, Colucci
Publikováno v:
Anticancer research. 26(3B)
Topotecan is able to cross the blood-brain barrier (BBB) and has been demonstrated to be active in brain metastases from small cell lung cancer (SCLC).The aim of this study was to evaluate the efficacy and toxicity of topotecan at a dosage of 1.5 mg/
Autor:
Silvio Orlando, Mario De Lena, Saverio Cinieri, Vito Lorusso, Gaetano Di Rienzo, Cosimo Brunetti, Mario Luigi Cisternino, Gaetano Napoli, Francesco Carpagnano, N. Panza, Salvatore Palazzo, Giuseppe Frasci
Publikováno v:
Scopus-Elsevier
PURPOSE: To determine the maximum-tolerated dose of gemcitabine when combined with a fixed dose of vinorelbine in the treatment of non–small-cell lung cancer (NSCLC) and to evaluate in a phase II trial the activity of this combination. PATIENTS AND
Autor:
Vito Lorusso, M. Spada, D. Germano, Cosimo Brunetti, Domenico Galetta, A. Misino, Vittorio Gebbia, G. Nettis, G. Cassano, D. Sambiasi
Publikováno v:
Journal of Clinical Oncology. 22:7314-7314
7314 Background: A number of second line treatments have been proposed in patients (pts) with advanced pretreated NSCLC. However, either single agents or two or three drug combinations achieved very poor results with no superiority of any combination
Autor:
Pasquale Cornella, Antonio Farris, Cosimo Brunetti, N. Panza, Enrico Barbato, Marina Licenziato, Dario Muci, Giuseppe Frasci, Giuseppe Comella, Luigi Maiorino
Publikováno v:
Lung Cancer. 41:S231
Autor:
S. Palmeri, N. Panza, Giuseppe Comella, Michele Di Natale, Cosimo Brunetti, Antonio Russo, A Lamberti, Pasquale Comella, D Muci, Giuseppe Frasci, G. De Cataldis, G.P. Nicolella, Ignazio Carreca
Publikováno v:
Lung Cancer. 29:51